Ozempic Maker Says AI Agents Are Shortening Its Clinical Trials
The Information
•
Generative AI
AI Research
In the ultracompetitive world of drug development, getting a new medication on the market as fast as possible can have major business implications. There’s perhaps no better recent example than Novo Nordisk, which has generated nearly $100B in sales of weight loss drugs Ozempic and Wegovy while trying to fend off competition from Eli Lilly. Now, Novo Nordisk says it’s using AI agents to shorten by weeks or months the time it takes to both start new clinical trials and to complete them.